Anika Therapeutics’ (ANIK) “Outperform” Rating Reiterated at Barrington Research

Barrington Research reissued their outperform rating on shares of Anika Therapeutics (NASDAQ:ANIK) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a $15.00 price objective on the biotechnology company’s stock.

Anika Therapeutics Stock Performance

Shares of Anika Therapeutics stock opened at $9.00 on Tuesday. The firm has a market cap of $129.78 million, a PE ratio of -2.17 and a beta of 0.63. Anika Therapeutics has a 1 year low of $7.87 and a 1 year high of $25.65. The firm’s 50-day simple moving average is $9.18 and its 200-day simple moving average is $11.63.

Institutional Investors Weigh In On Anika Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ANIK. Opaleye Management Inc. raised its stake in Anika Therapeutics by 49.1% during the second quarter. Opaleye Management Inc. now owns 588,797 shares of the biotechnology company’s stock worth $6,229,000 after acquiring an additional 193,797 shares during the period. Capital Management Corp VA raised its stake in Anika Therapeutics by 24.0% during the second quarter. Capital Management Corp VA now owns 408,845 shares of the biotechnology company’s stock worth $4,326,000 after acquiring an additional 79,185 shares during the period. Cove Street Capital LLC acquired a new stake in Anika Therapeutics during the first quarter worth about $1,126,000. Acadian Asset Management LLC raised its stake in Anika Therapeutics by 13.4% during the first quarter. Acadian Asset Management LLC now owns 539,614 shares of the biotechnology company’s stock worth $8,107,000 after acquiring an additional 63,901 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Anika Therapeutics in the first quarter valued at approximately $621,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.